Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 2
2022 3
2023 4
2024 8
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer.
Zhou J, He M, Zhao Q, Shi E, Wang H, Ponkshe V, Song J, Wu Z, Ji D, Kranz G, Tscherne A, Schwenk-Zieger S, Razak NA, Hess J, Belka C, Zitzelsberger H, Ourailidis I, Stögbauer F, Boxberg M, Budczies J, Reichel CA, Canis M, Baumeister P, Wang H, Unger K, Mock A, Gires O. Zhou J, et al. Among authors: tscherne a. Mol Cancer. 2025 Mar 22;24(1):94. doi: 10.1186/s12943-025-02290-1. Mol Cancer. 2025. PMID: 40121428 Free PMC article.
Treatment of myopic choroidal neovascularization: a network meta-analysis and review.
Glachs L, Embacher S, Berghold A, Wildner B, Michelitsch M, Tscherne A, Wedrich A, Posch-Pertl L. Glachs L, et al. Among authors: tscherne a. Graefes Arch Clin Exp Ophthalmol. 2024 Jun;262(6):1693-1722. doi: 10.1007/s00417-023-06271-2. Epub 2023 Nov 11. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37950753 Free PMC article. Review.
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
Link EK, Tscherne A, Sutter G, Smith ER, Gurwith M, Chen RT, Volz A; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Link EK, et al. Among authors: tscherne a. Vaccine. 2025 Jan 1;43(Pt 1):126521. doi: 10.1016/j.vaccine.2024.126521. Epub 2024 Nov 28. Vaccine. 2025. PMID: 39612556 Free article. Review.
Mucosal COVID-19 vaccines in clinical development.
Tscherne A, Sun W, Liu STH, Krammer F. Tscherne A, et al. Vaccine. 2025 Sep 17;63:127602. doi: 10.1016/j.vaccine.2025.127602. Epub 2025 Aug 22. Vaccine. 2025. PMID: 40848675 Free article. Review.
A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.
Kubinski M, Beicht J, Zdora I, Biermann J, Puff C, Gerlach T, Tscherne A, Baumgärtner W, Osterhaus ADME, Sutter G, Prajeeth CK, Rimmelzwaan GF. Kubinski M, et al. Among authors: tscherne a. Front Immunol. 2023 Apr 21;14:1182963. doi: 10.3389/fimmu.2023.1182963. eCollection 2023. Front Immunol. 2023. PMID: 37153588 Free PMC article.
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Raadsen MP, et al. Lancet Infect Dis. 2025 Feb;25(2):231-242. doi: 10.1016/S1473-3099(24)00423-7. Epub 2024 Oct 7. Lancet Infect Dis. 2025. PMID: 39389076 Clinical Trial.
27 results